Ann: Novartis and Mesoblast Remestemcel-L Collaboration, page-365

@stockrock

“then SR-aGVHD is simply not financially feasible to pursue”.

I agree. From a business point of view, given the market size and costs involved in a brand new trial with no guarantees of success and lower lying, much juicier fruit all around? It’s a no brainer!

Now approach it from the perspective of the people side. I’ll cut to the chase: Relationship between SI (with the MSB team I assume) and Dr Joanne Kurtzberg.

MSB will chase this to the end and do the trial if all other options don’t get them the desired result. My opinion of course. I’m pretty certain though. History shows it.

This has the potential to change the MSB business and its management and board.

Early days of course and if it doesn’t come to that then we may never know. We are getting closer to the point of full commercialisation - the business end of things, where the science is proven and accountants gain power - a gun accountant has recently been appointed I’m sure you have noticed. Pioneering entrepreneurial business people rarely make for good day to day managers.

If it came down to a shareholders vote to determine whether MSB enters into another trial with all costs on MSB, how would you vote, knowing it may never recoup the costs to do it?